32 hours ago · Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. >> Go To The Portal
Because of the public health importance of a vaccine to prevent EVD, the FDA worked closely with the company and completed its evaluation of the safety and effectiveness of Ervebo in less than six months. The approval was granted to Merck & Co., Inc.
The Ebola virus vaccine ERVEBO® (Ebola Zaire Vaccine, Live also known as V920, rVSVΔG-ZEBOV-GP or rVSV-ZEBOV) is approved by the U.S. Food and Drug Administration (FDA) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older as a single dose administration.
Ebola vaccine: Antibodies persist after 6 months.
In December 2016, a study found the VSV-EBOV vaccine to be 95–100% effective against the Ebola virus, making it the first proven vaccine against the disease. The approval was supported by a study conducted in Guinea during the 2014–2016 outbreak in individuals 18 years of age and older.
Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies. There is no commercially available vaccine against EBOV.
There's currently no licensed treatment or vaccine for Ebola virus disease, although vaccines and drug therapies are being developed and tested. Any area where an outbreak happens should be immediately quarantined, and people who have the infection should be treated in isolation in intensive care.
To date, more than 250,000 individuals participating in clinical trials and vaccination initiatives have received at least the first dose of the Johnson & Johnson Ebola vaccine regimen, including 200,000 who have been fully vaccinated.
Have these vaccines been used before? The Ervebo vaccine has been used under “expanded access” or what is also known as “compassionate use” for 16 000 people in Guinea in 2015 and for 345 000 people during the 2018-2020 outbreaks in the Democratic Republic of the Congo.
The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks.
Brief Summary: This study will test the safety of an experimental vaccine developed to protect against Ebola virus infection and to determine if the vaccine induces an immune response to the virus.
Major innate immunity mechanisms against Ebola are associated with the production of interferons, that are inhibited by viral proteins. Activation of host NK cells was recognized as a leading immune function responsible for recovery of infected people.
That's because viruses are small molecules that produce only a handful of proteins, so there are fewer "targets" for treatment, Gatherer said. For this same reason, it has been hard to develop a vaccine against Ebola; a person's immune system (which is primed by vaccines) has a small target, Gatherer said.
Have these vaccines been used before? The Ervebo vaccine has been used under “expanded access” or what is also known as “compassionate use” for 16 000 people in Guinea in 2015 and for 345 000 people during the 2018-2020 outbreaks in the Democratic Republic of the Congo.
NIAID and Okairos (a company later acquired by GSK) developed an Ebola vaccine candidate (now licensed to the Sabin Vaccine Institute) that uses a chimpanzee adenovirus (cAd3) vector, or carrier, to deliver Ebola genetic material.
The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks.
Ebola vaccine 'sitting on shelf' Canada donated 800 doses of its experimental vaccine for use during the outbreak. The federal government also continued to provide support for the clinical trials, including a Phase 1 trial at the Canadian Centre for Vaccinology in Halifax.